Palivizumab for Severe Respiratory Syncytial Virus Infection in Immunocompetent Adults: A Case Series
Abstract
Background Respiratory syncytial virus (RSV) is a significant cause of lower respiratory tract infections in adults, particularly the elderly, and can lead to severe outcomes, including respiratory failure. Current treatment options for RSV in immunocompetent adults are limited to supportive care. Objective This case series aims to describe the clinical course and outcomes of two immunocompetent adults with severe RSV infection treated with Palivizumab, a monoclonal antibody against RSV. Methods We report two cases: a 92-year-old female with a history of hypertension and a previous meningioma resection, and a 42-year-old female with no significant past medical history. Both presented with severe respiratory symptoms, were diagnosed with RSV infection via PCR, and received a single dose of intramuscular Palivizumab (approximately 12–13 mg/kg) after initial clinical deterioration despite supportive care and empiric antibiotic therapy. Results Following Palivizumab administration, both patients exhibited clinical improvement, including resolution of fever and improvement in oxygenation and radiographic findings. Both patients were discharged in stable condition without the need for supplemental oxygen. Conclusion These cases suggest that Palivizumab may be a potential therapeutic option for severe RSV infection in immunocompetent adults. Further research, including randomized controlled trials, is needed to confirm these preliminary findings and establish optimal dosing and…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.